May 26, 2022
Video
With limitations on fidaxomicin at their facility, a hospital looked at vancomycin usage to determine if they needed to align with the new IDSA/SHEA CDI treatment guideline.
May 24, 2022
Article
New information suggests a few more cases have surfaced in the United States, pending CDC confirmation.
January 31, 2022
The approval of the Spikevax vaccine was based on safety and efficacy data approximately 6 months after the second dose.
December 22, 2021
The relative risk reduction was 94% in patients 65 years of age or older in clinical trials.
Gina Poe, PhD: How Psychiatric Diseases Impact Sleep Health
Madeline Belk, PharmD, Discusses Oral Vancomycin as a First-Line CDI Therapy
Low Prevalence of Keratosis Pilaris in Patients with Atopic Dermatitis